Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan
Author:
Affiliation:
1. Clinical Research, Center for Molecular Medicine and Immunology, Mendham, NJ, USA
Funder
National Cancer Institute
Publisher
Informa UK Limited
Subject
Immunology,Immunology and Allergy
Link
https://www.tandfonline.com/doi/pdf/10.1080/19420862.2019.1632115
Reference66 articles.
1. Antibody-Drug Conjugates in Cancer Therapy
2. Antibody-drug conjugates: an emerging modality for the treatment of cancer
3. Prospects and progress of antibody-drug conjugates in solid tumor therapies
4. Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes
5. Antibody-Drug Conjugate-Based Therapeutics: State of the Science
Cited by 93 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Acid-sensitive prodrugs; a promising approach for site-specific and targeted drug release;European Journal of Medicinal Chemistry;2024-10
2. Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study;Future Oncology;2024-09-12
3. New Advances in Metastatic Urothelial Cancer: A Narrative Review on Recent Developments and Future Perspectives;International Journal of Molecular Sciences;2024-09-07
4. Natural-source payloads used in the conjugated drugs architecture for cancer therapy: Recent advances and future directions;Pharmacological Research;2024-09
5. Antibody-drug conjugates for hepato-pancreato-biliary malignancies: “Magic bullets” to the rescue?;Cancer Treatment Reviews;2024-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3